Altimmune (ALT) Share-based Compensation (2010 - 2026)

Altimmune (ALT) has 17 years of Share-based Compensation data on file, last reported at $3.4 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $3.4 million, down 15.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.4 million (up 4.61% YoY), and the FY2025 annual result was $16.1 million, up 11.69% from the prior year.
• Share-based Compensation slipped to $3.4 million in Q1 2026 per ALT's latest filing, from $4.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.9 million in Q4 2025 and troughed at $1.9 million in Q4 2022.
• A 5-year average of $3.1 million and a median of $3.1 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 166812.97% in 2022, then declined 17.28% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $1.9 million in 2022, then surged by 30.5% to $2.5 million in 2023, then surged by 35.84% to $3.4 million in 2024, then jumped by 47.32% to $4.9 million in 2025, then sank by 31.63% to $3.4 million in 2026.
• Business Quant data shows ALT's Share-based Compensation at $3.4 million in Q1 2026, $4.9 million in Q4 2025, and $3.6 million in Q3 2025.